Levi & Korsinsky Announces Class Action Lawsuit for Regeneron Shareholders

In recent news, shareholders who experienced financial losses due to Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) are urged to contact Levi & Korsinsky, LLP, as the firm has initiated a class action lawsuit against the biopharmaceutical giant. This case comes in response to allegations of securities fraud that potentially impacted investors between November 2, 2023, and October 30, 2024.

Understanding the Allegations

The current lawsuit seeks to hold the company accountable for a series of misleading statements and actions regarding its flagship product, Eylea. Key allegations suggest that Regeneron engaged in practices designed to misrepresent the pricing structures and sales performance of Eylea, which is critical in treating retinal diseases.

The complaint states that Regeneron allegedly paid credit card fees to distributors which allowed them to charge Eylea customers lower prices when using a credit card. However, these practices effectively inflated the sales figures reported by Regeneron, misleading both investors and federal agencies.

Specifically, the company is accused of:
1. Paying distributors to keep credit card charges low, ultimately subsidizing prices that customers faced when buying Eylea with credit cards.
2. Creating an illusion of greater sales success by concealing the true cost concessions that should have been reported.
3. Violating the False Claims Act due to discrepancies in Average Selling Prices (ASP) reported to federal authorities, affecting reimbursement rates.

Implications for Shareholders

For investors who suffered losses during the specified period, it’s crucial to respond promptly. Levi & Korsinsky emphasizes that shareholders have until March 10, 2025, to file for lead plaintiff status in this class action. Although serving as a lead plaintiff is not a requisite for recovery, it could play a pivotal role in the lawsuit's proceedings.

What’s particularly noteworthy is that there are no upfront costs for class members who decide to join the lawsuit. This opens opportunities for investors to recover potential losses without financial burdens for legal fees.

Why Choose Levi & Korsinsky?

With over 20 years of experience, Levi & Korsinsky, LLP, has demonstrated its prowess in securing substantial settlements for shareholders. The firm has represented various clients in similar high-stakes securities litigation, achieving significant victories. Notably, it boasts a dedicated team of over 70 professionals committed to navigating complex legal landscapes.

Joe Levi, the firm's founder, has been recognized in the industry, with the firm consistently ranked in the top 50 securities litigation firms in the United States. This extensive experience instills confidence among investors looking to recover their losses through the legal system.

Next Steps for Investors

If you are a shareholder who has faced financial losses from your investment in Regeneron, now is the time to take action. Interested parties can get in touch with Levi & Korsinsky via their official website or contact Joseph E. Levi directly at (212) 363-7500 or through email at [email protected]

This class action marks a significant moment in holding corporations accountable for transparency in their financial disclosures and supporting impacted investors in reclaiming their rightful losses.